Search results
Results from the WOW.Com Content Network
On Friday, KARL STORZ Endoscopy-America, Inc. agreed to acquire Asensus Surgical Inc. (NYSE:ASXC) for $0.35 per share in cash. KARL STORZ is a wholly-owned direct subsidiary of KARL STORZ SE & Co ...
Intuitive Surgical (NASDAQ: ISRG) is a healthcare company that makes robotic-assisted surgical devices. Intuitive Surgical's stock has been rallying, and it's up around 60% over the past 12 months.
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. [2] Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as ...
Robot-assisted surgery or robotic surgery are any types of surgical procedures that are performed using robotic systems. Robotically assisted surgery was developed to try to overcome the limitations of pre-existing minimally-invasive surgical procedures and to enhance the capabilities of surgeons performing open surgery.
MAKO Surgical was founded in 2004 by Rony Abovitz and other key members of its predecessor Z-KAT, Inc. [9] Z-KAT was founded in 1997 by Rony Abovitz, William Tapia, Michael Peshkin Ph.D., Julio Santos-Munne, and Wayne J. Kerness, M.D. and was developing a novel haptic robotic system for medical applications, amongst a wide variety of computer-assisted surgery technologies.
In this article, we will be taking a look at the 10 best robotic stocks under $10. To skip our discussion on the robotics industry, you can go directly to the 5 Best Robotic Stocks Under $10.
Stock name Symbol Country of origin A. O. Smith Corporation: AOS: US A10 Networks, Inc. ATEN: US AAC Holdings Inc. AAC: US AAR Corporation: AIR: US Aaron's Inc.
It is the world's largest maker of implants to mend bone fractures, [2] and also produces surgical power tools and advanced biomaterials. In June 2012 Synthes was sold by its chairman, former CEO and largest shareholder Hansjörg Wyss to Johnson & Johnson for $20.2 billion. [3] The company is part of Johnson & Johnson MedTech business segment. [4]